AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32122726 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 77
Study 34792531 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cycles of fluorouracil, leucovorin, and oxaliplatin before fluorouracil/oxaliplatin CRT (50.4 Gy)
Number of subjects: 311
Study 34792531 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy (CRT) before chemotherapy
Number of subjects: 311
Study 34792531 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision
Number of subjects: 311
Study 34792531 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool incontinence assessment
Number of subjects: 311
Study 33508240 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 0
Study 33508240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35101166 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based care (delegation of physicians' tasks to specialized rheumatological assistants)
Number of subjects: 601
Study 35101166 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 601
Study 35101166 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based care
Number of subjects: 601
Study 34359567 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based physical activity support program (IPAS)
Number of subjects: 137
Study 34359567 — intervention group
Group type: EXPERIMENTAL
Intervention: IPAS combined with physiotherapist telephone counselling (blended care)
Number of subjects: 137
Study 34359567 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 137
Study 35365302 — intervention group
Group type: COMPARATOR
Intervention: Targeted Gene Panel Testing (TGPT) of 4 oncogenes (ALK, BRAF, EGFR, ROS1)
Number of subjects: 10000
Study 35365302 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive Genomic Profiling (CGP) of 10 oncogenes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1, NTRK2, NTRK3, RET, ROS1)
Number of subjects: 10000
Study 35365302 — intervention group
Group type: EXPERIMENTAL
Intervention: No tumor profiling (no genes tested)
Number of subjects: 10000
Study 32284058 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PVP)
Number of subjects: 56
Study 32284058 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous kyphoplasty (PKP)
Number of subjects: 56
Study 33047321 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention including marine omega-3 fatty acids, olive oil, and vitamin D
Number of subjects: 55
Study 33047321 — intervention group
Group type: COMPARATOR
Intervention: Placebo equivalents
Number of subjects: 55
Study 33047321 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 55
Study 33047321 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 33047321 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthier diet
Number of subjects: 55
Study 33129376 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (800 mg per day orally) plus bortezomib (1·3 mg/m2) and dexamethasone (20 mg orally)
Number of subjects: 291
Study 33129376 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus bortezomib (1·3 mg/m2) and dexamethasone (20 mg orally)
Number of subjects: 291
Study 33129376 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 291
Study 33129376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 33740110 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet at low pressures (100 mmHg above systolic blood pressure)
Number of subjects: 71
Study 33740110 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet (Control group)
Number of subjects: 71
Study 33438529 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DIZI-guided injections
Number of subjects: 0
Study 33438529 — intervention group
Group type: COMPARATOR
Intervention: Standard ultrasound-guided injections
Number of subjects: 0
Study 32565133 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinflunine plus Best Supportive Care (VFL + BSC)
Number of subjects: 87
Study 32565133 — intervention group
Group type: COMPARATOR
Intervention: Best Supportive Care (BSC) alone
Number of subjects: 87
Study 35915405 — intervention group
Group type: EXPERIMENTAL
Intervention: STROKE-CARD care
Number of subjects: 2149
Study 35915405 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2149
Study 33754755 — intervention group
Group type: EXPERIMENTAL
Intervention: Reservoir Computing (RC) with linear activation and quadratic readout
Number of subjects: 0
Study 33754755 — intervention group
Group type: EXPERIMENTAL
Intervention: Reservoir Computing (RC) with identity activation function
Number of subjects: 0
Study 33754755 — intervention group
Group type: COMPARATOR
Intervention: Vector Autoregressive (VAR) models
Number of subjects: 0
Study 33754755 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Mode Decomposition (DMD)
Number of subjects: 0
Study 2004928420 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS/Real tACS (ACDC)
Number of subjects: 24
Study 2004928420 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS/Real tACS (AC)
Number of subjects: 24
Study 2004928420 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS/Sham tACS (Sham)
Number of subjects: 24
Study 35329279 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioception training
Number of subjects: 45
Study 35329279 — intervention group
Group type: COMPARATOR
Intervention: Routine conservative physiotherapy treatment
Number of subjects: 45
Study 33817894 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative therapy in addition to standard care
Number of subjects: 100
Study 33817894 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study 32148255 — intervention group
Group type: EXPERIMENTAL
Intervention: Recycled water
Number of subjects: 1264
Study 32148255 — intervention group
Group type: COMPARATOR
Intervention: Reclaimed water
Number of subjects: 1264
Study 34331996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 100
Study 34331996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 34755389 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml of semi‐skimmed milk containing approximately 600 mg of calcium with 200 µg of cholecalciferol
Number of subjects: 20
Study 34755389 — intervention group
Group type: COMPARATOR
Intervention: 500 ml of water with 200 µg of cholecalciferol
Number of subjects: 20
Study 36196926 — intervention group
Group type: EXPERIMENTAL
Intervention: weCare intervention (n = 100)
Number of subjects: 198
Study 36196926 — intervention group
Group type: COMPARATOR
Intervention: usual-care (n = 98)
Number of subjects: 198
Study 32885875 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-focus (DF) contact lens
Number of subjects: 28
Study 32885875 — intervention group
Group type: COMPARATOR
Intervention: Single-vision (SV) contact lens
Number of subjects: 28
Study 35246030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus dose, followed by a 2 mg/kg/h continuous infusion)
Number of subjects: 100
Study 35246030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 100
Study 35246030 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study 36410561 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Modification (low-fat diet with increased vegetable, fruit, and grain intake)
Number of subjects: 23217
Study 36410561 — intervention group
Group type: COMPARATOR
Intervention: Usual diet without modification (Control)
Number of subjects: 23217
Study 34650833 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose Aldesleukin (HD rIL-2) followed by Ipilimumab (IPI)
Number of subjects: 29
Study 34650833 — intervention group
Group type: EXPERIMENTAL
Intervention: HD rIL-2 followed by IPI
Number of subjects: 29
Study 34650833 — intervention group
Group type: EXPERIMENTAL
Intervention: IPI followed by HD rIL-2
Number of subjects: 29
Study 34650833 — intervention group
Group type: COMPARATOR
Intervention: Both arms (HD rIL-2 and IPI)
Number of subjects: 29
Study 34650833 — intervention group
Group type: EXPERIMENTAL
Intervention: HD rIL-2
Number of subjects: 29
Study 33174437 — intervention group
Group type: EXPERIMENTAL
Intervention: Village health workers (VHWs) in rural communities
Number of subjects: 429
Study 33174437 — intervention group
Group type: COMPARATOR
Intervention: Urban VHWs
Number of subjects: 429
Study 33174437 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural VHWs
Number of subjects: 429
Study 33174437 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of VHWs
Number of subjects: 429
Study 36097694 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral approach
Number of subjects: 555
Study 36097694 — intervention group
Group type: COMPARATOR
Intervention: Direct lateral approach
Number of subjects: 555
Study 36097694 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 555
Study 34882062 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological factors (personality factors, symptoms of depression and anxiety, perceived stress)
Number of subjects: 1219
Study 32362168 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice
Number of subjects: 671
Study 32362168 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements
Number of subjects: 671
Study 32362168 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice combined with oral nutritional supplements
Number of subjects: 671
Study 32362168 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 671
Study 36263240 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical spinal decompression therapy (NSDT), performed ten times in eight weeks
Number of subjects: 60
Study 36263240 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical spinal decompression therapy (NSDT)
Number of subjects: 60
Study 33598937 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (bMI)
Number of subjects: 0
Study 33598937 — intervention group
Group type: COMPARATOR
Intervention: Educational session on breastfeeding (control)
Number of subjects: 0
Study 33302782 — intervention group
Group type: EXPERIMENTAL
Intervention: Attend to Source Instructions
Number of subjects: 102
Study 33302782 — intervention group
Group type: COMPARATOR
Intervention: Control Instructions
Number of subjects: 102
Study 32565480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative irrigation and subdural drainage
Number of subjects: 540
Study 32565480 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative irrigation and subdural drainage
Number of subjects: 540
Study 32418302 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning Algorithm (LA)
Number of subjects: 21
Study 32418302 — intervention group
Group type: COMPARATOR
Intervention: Physician Adjustments (PA)
Number of subjects: 21
Study 33516710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alcohol titrated to 0.08% blood alcohol concentration
Number of subjects: 100
Study 33516710 — intervention group
Group type: COMPARATOR
Intervention: Placebo (volume and osmolarity-matched, masked)
Number of subjects: 100
Study 32268554 — intervention group
Group type: COMPARATOR
Intervention: Control drink (2 kcal)
Number of subjects: 26
Study 32268554 — intervention group
Group type: EXPERIMENTAL
Intervention: P280 (70 g protein, 0 g fat, 0 g carbohydrate, 280 kcal)
Number of subjects: 26
Study 32268554 — intervention group
Group type: EXPERIMENTAL
Intervention: M280 (14 g protein, 12.4 g fat, 28 g carbohydrate, 280 kcal)
Number of subjects: 26
Study 32268554 — intervention group
Group type: EXPERIMENTAL
Intervention: M504 (70 g protein, 12.4 g fat, 28 g carbohydrate, 504 kcal)
Number of subjects: 26
Study 32268554 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric drinks
Number of subjects: 26
Study 32721228 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 200 mg
Number of subjects: 100
Study 32721228 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 400 mg
Number of subjects: 100
Study 32721228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 32721228 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (200 mg and 400 mg combined)
Number of subjects: 100
Study 32609653 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy treatment
Number of subjects: 50
Study 34342122 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed method for interval estimation
Number of subjects: 0
Study 34342122 — intervention group
Group type: EXPERIMENTAL
Intervention: Real data on adverse events in a clinical trial
Number of subjects: 0
Study 34049835 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 50
Study 34049835 — intervention group
Group type: COMPARATOR
Intervention: Orthokin mouthwash
Number of subjects: 50
Study 35709728 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine gastric residual aspiration
Number of subjects: 51
Study 35709728 — intervention group
Group type: COMPARATOR
Intervention: Nonroutine gastric residual aspiration
Number of subjects: 51
Study 34240282 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-months multi-component exercise program (28 sessions of strength and balance exercises)
Number of subjects: 378
Study 34240282 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 378
Study 32164882 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 12844
Study 32164882 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 12844
Study 34822741 — intervention group
Group type: EXPERIMENTAL
Intervention: PACAP38 (10 pmol/kg/min)
Number of subjects: 44
Study 34822741 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal polypeptide (8 pmol/kg/min)
Number of subjects: 44
Study 34264994 — intervention group
Group type: EXPERIMENTAL
Intervention: Elamipretide (ELAM)
Number of subjects: 39
Study 34264994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 35487526 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated dose radiotherapy (62 Gy to primary tumour, 50.4 Gy to surrounding mesorectum in 28 fractions) with concurrent chemotherapy (capecitabine, 5-fluorouracil/leucovorin or omitted)
Number of subjects: 104
Study 35487526 — intervention group
Group type: COMPARATOR
Intervention: 50.4 Gy to the primary tumour and surrounding mesorectum with concurrent chemotherapy (capecitabine, 5-fluorouracil/leucovorin or omitted)
Number of subjects: 104
Study 34965712 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation complex including therapeutic exercises, mechanotherapy, electrical stimulation, gravitational therapy, and antiresorptive therapy (10 procedures)
Number of subjects: 40
Study 34965712 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation complex including therapeutic exercises, mechanotherapy, electrical stimulation (10 procedures)
Number of subjects: 40
Study 34965712 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation complex including gravitational therapy and antiresorptive therapy
Number of subjects: 40
Study 33316689 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (2 mg/day, target trough level: 4-6 ng/mL) for six months
Number of subjects: 10
Study 33316689 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 10
Study 32301225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreas and kidney transplantation
Number of subjects: 43
Study 35680613 — intervention group
Group type: EXPERIMENTAL
Intervention: GI Genius™-assisted colonoscopy (GGC)
Number of subjects: 1828
Study 35680613 — intervention group
Group type: COMPARATOR
Intervention: Standard Colonoscopy (SC)
Number of subjects: 1828
Study 34002558 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal penetrating moxibustion, approximately 50 min each time, once a day, for 4 weeks
Number of subjects: 62
Study 34002558 — intervention group
Group type: COMPARATOR
Intervention: Routine basic treatment, acupuncture treatment, and rehabilitation training
Number of subjects: 62
Study 35232310 — intervention group
Group type: EXPERIMENTAL
Intervention: No compression
Number of subjects: 104
Study 35232310 — intervention group
Group type: COMPARATOR
Intervention: Compression (class II thigh-high)
Number of subjects: 104
Study 32100917 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% atropine eyedrops
Number of subjects: 153
Study 32100917 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 153
Study 35538329 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint (OS)
Number of subjects: 21
Study 35538329 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS)
Number of subjects: 21
Study 35538329 — intervention group
Group type: COMPARATOR
Intervention: No device (reference night)
Number of subjects: 21
Study 36328113 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with implantable loop recorder (ILR) and subsequent anticoagulation upon detection of new-onset AF episodes ≥6 min
Number of subjects: 1997
Study 36328113 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1997
Study 32052567 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Cognition and Interaction Training (SCIT)
Number of subjects: 16
Study 32052567 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation group
Number of subjects: 16
Study 32511143 — intervention group
Group type: COMPARATOR
Intervention: Control group received infiltration of 0.5% bupivacaine 100 mg (20 mL) and epinephrine 0.5 mg (0.5 mL)
Number of subjects: 80
Study 32511143 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal group received infiltration with 0.5% bupivacaine 92.5 mg (18.5 mL), ketorolac 30 mg (1 mL), morphine 5 mg (0.5 mL), and epinephrine 0.5 mg (0.5 mL)
Number of subjects: 80
Study 32511143 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 32511143 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal group
Number of subjects: 80
Study 35168972 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Living with Insomnia (MLWI)
Number of subjects: 250
Study 35168972 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy for Insomnia (CBT-I)
Number of subjects: 250
Study 33779579 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 1072
Study 33779579 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 1072
Study 32296223 — intervention group
Group type: EXPERIMENTAL
Intervention: McConnell taping combined with strengthening exercises of vastus medialis oblique muscle
Number of subjects: 51
Study 32296223 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 51
Study 35140342 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab plus cisplatin-radiation (NCRT)
Number of subjects: 404
Study 35140342 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-radiation (CRT)
Number of subjects: 404
Study 34711224 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix 10 mg
Number of subjects: 216
Study 34711224 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix 20 mg
Number of subjects: 216
Study 34711224 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix 40 mg
Number of subjects: 216
Study 34711224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 34351426 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐blocker therapy (agent and dose according to treating physician)
Number of subjects: 0
Study 34351426 — intervention group
Group type: COMPARATOR
Intervention: No β‐blocker therapy
Number of subjects: 0
Study 32954412 — intervention group
Group type: EXPERIMENTAL
Intervention: blue‐depleted light environment
Number of subjects: 12
Study 32954412 — intervention group
Group type: COMPARATOR
Intervention: normal lighting
Number of subjects: 12
Study 32157626 — intervention group
Group type: EXPERIMENTAL
Intervention: LAN new syringe
Number of subjects: 90
Study 32157626 — intervention group
Group type: COMPARATOR
Intervention: octreotide LAR syringe
Number of subjects: 90
Study 35910893 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone ZTEx intervention (15-min face-to-face session + 12-week ZTEx instant messaging with 28 picture e-messages and ZTExApp)
Number of subjects: 139
Study 35910893 — intervention group
Group type: COMPARATOR
Intervention: Control group (same duration of individual session and number and format of e-messages, but content was healthy eating and breathing exercise)
Number of subjects: 139
Study 32985108 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat meal (20% fat, 60% carbohydrate, 20% protein; FQ = 0.899)
Number of subjects: 8
Study 32985108 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (60% fat, 20% carbohydrate, 20% protein; FQ = 0.784)
Number of subjects: 8
Study 35927732 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision support tools for chemoprevention
Number of subjects: 7
Study 35189589 — intervention group
Group type: EXPERIMENTAL
Intervention: MFG-PP (Multiple Family Group - Parent Peers)
Number of subjects: 2391
Study 35189589 — intervention group
Group type: EXPERIMENTAL
Intervention: MFG-CHW (Multiple Family Group - Community Health Workers)
Number of subjects: 2391
Study 35189589 — intervention group
Group type: COMPARATOR
Intervention: Comparison with other family-based interventions
Number of subjects: 2391
Study 33793040 — intervention group
Group type: COMPARATOR
Intervention: Artificially reduced depth of penetration using silicone rings around the base of the man's erect penis.
Number of subjects: 12
Study 32758087 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) - 60 J per site, 6 sites per limb, total dose = 360 J
Number of subjects: 14
Study 32758087 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 14
Study 34197956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mL (0.75%) infiltrated into the retroperitoneal space overlying the superior hypogastric plexus
Number of subjects: 50
Study 34197956 — intervention group
Group type: COMPARATOR
Intervention: No block given at the completion of surgery
Number of subjects: 50
Study 33301153 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted kappa used for multilevel outcomes
Number of subjects: 0